{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Unknown/Not Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"The best overall response is defined as the best response recorded from the start of the treatment until disease progression (PD)/recurrence. Per RECIST: CR, the disappearance of all target and non-target lesions; PR, at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the Baseline sum LD; SD, neither sufficient shrinkage in target lesions to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started and the persistence of one or more non-target lesion(s); PD, at least a 20% increase in the sum of the LD of target lesions, taking as a reference the smallest sum of the LD recorded since the treatment started or the appearance of \\>=1 new lesion and/or unequivocal progression of existing non-target lesions. Unknown/not evaluable is used for those participants who cannot be classified as achieving CR, PR, SD, or PD.","groups":[{"description":"Participants received pazopanib 800 milligrams (mg) once daily.","id":"OG000","title":"Pazopanib 800 mg"}],"paramType":"NUMBER","populationDescription":"ATS Population","reportingStatus":"POSTED","timeFrame":"From the Baseline to Week 24/investigational product discontinuation (up to 3.460 years)","title":"Number of Participants With the Indicated Best Overall Response","type":"SECONDARY","unitOfMeasure":"participants"}